Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 1
2008 1
2009 2
2010 1
2011 3
2012 2
2013 3
2014 2
2015 2
2016 2
2017 1
2018 5
2019 3
2020 2
2021 13
2022 8
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, Neuzil KM, Hahn W, Hunt J, Mulligan MJ, McEvoy C, DeJesus E, Hassman M, Little SJ, Pahud BA, Durbin A, Pickrell P, Daar ES, Bush L, Solis J, Carr QO, Oyedele T, Buchbinder S, Cowden J, Vargas SL, Guerreros Benavides A, Call R, Keefer MC, Kirkpatrick BD, Pullman J, Tong T, Brewinski Isaacs M, Benkeser D, Janes HE, Nason MC, Green JA, Kelly EJ, Maaske J, Mueller N, Shoemaker K, Takas T, Marshall RP, Pangalos MN, Villafana T, Gonzalez-Lopez A; AstraZeneca AZD1222 Clinical Study Group. Falsey AR, et al. N Engl J Med. 2021 Dec 16;385(25):2348-2360. doi: 10.1056/NEJMoa2105290. Epub 2021 Sep 29. N Engl J Med. 2021. PMID: 34587382 Free PMC article. Clinical Trial.
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, Barnett ED, Muñoz FM, Maldonado Y, Pahud BA, Domachowske JB, Simões EAF, Sarwar UN, Kitchin N, Cunliffe L, Rojo P, Kuchar E, Rämet M, Munjal I, Perez JL, Frenck RW Jr, Lagkadinou E, Swanson KA, Ma H, Xu X, Koury K, Mather S, Belanger TJ, Cooper D, Türeci Ö, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591007 Clinical Trial Group. Walter EB, et al. Among authors: talaat kr. N Engl J Med. 2022 Jan 6;386(1):35-46. doi: 10.1056/NEJMoa2116298. Epub 2021 Nov 9. N Engl J Med. 2022. PMID: 34752019 Free PMC article.
Editorial: Immunological aspects of vaccine safety.
Vajdy M, Rath BA, Talaat KR. Vajdy M, et al. Among authors: talaat kr. Front Immunol. 2023 Aug 18;14:1212148. doi: 10.3389/fimmu.2023.1212148. eCollection 2023. Front Immunol. 2023. PMID: 37662921 Free PMC article. No abstract available.
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age.
Muñoz FM, Sher LD, Sabharwal C, Gurtman A, Xu X, Kitchin N, Lockhart S, Riesenberg R, Sexter JM, Czajka H, Paulsen GC, Maldonado Y, Walter EB, Talaat KR, Englund JA, Sarwar UN, Hansen C, Iwamoto M, Webber C, Cunliffe L, Ukkonen B, Martínez SN, Pahud BA, Munjal I, Domachowske JB, Swanson KA, Ma H, Koury K, Mather S, Lu C, Zou J, Xie X, Shi PY, Cooper D, Türeci Ö, Şahin U, Jansen KU, Gruber WC; C4591007 Clinical Trial Group. Muñoz FM, et al. Among authors: talaat kr. N Engl J Med. 2023 Feb 16;388(7):621-634. doi: 10.1056/NEJMoa2211031. N Engl J Med. 2023. PMID: 36791162 Free PMC article. Clinical Trial.
Risk of COVID-19 after natural infection or vaccination.
Rick AM, Laurens MB, Huang Y, Yu C, Martin TCS, Rodriguez CA, Rostad CA, Maboa RM, Baden LR, El Sahly HM, Grinsztejn B, Gray GE, Gay CL, Gilbert PB, Janes HE, Kublin JG, Huang Y, Leav B, Hirsch I, Struyf F, Dunkle LM, Neuzil KM, Corey L, Goepfert PA, Walsh SR, Follmann D, Kotloff KL; NIAID-funded COVID-19 Prevention Network (CoVPN). Rick AM, et al. EBioMedicine. 2023 Oct;96:104799. doi: 10.1016/j.ebiom.2023.104799. Epub 2023 Sep 20. EBioMedicine. 2023. PMID: 37738833 Free PMC article. Clinical Trial.
The way forward for ETEC controlled human infection models (CHIMs).
Hanevik K, Chen WH, Talaat KR, Porter C, Bourgeois L. Hanevik K, et al. Among authors: talaat kr. Vaccine. 2019 Aug 7;37(34):4794-4799. doi: 10.1016/j.vaccine.2019.01.003. Epub 2019 Jan 29. Vaccine. 2019. PMID: 30709728 Free article. Review.
Critical Needs in Advancing Shigella Vaccines for Global Health.
MacLennan CA, Talaat KR, Kaminski RW, Cohen D, Riddle MS, Giersing BK. MacLennan CA, et al. Among authors: talaat kr. J Infect Dis. 2022 May 4;225(9):1500-1503. doi: 10.1093/infdis/jiab462. J Infect Dis. 2022. PMID: 34558631 Free PMC article.
Shigella-Controlled Human Infection Models: Current and Future Perspectives.
Clarkson KA, Porter CK, Talaat KR, Kapulu MC, Chen WH, Frenck RW Jr, Bourgeois AL, Kaminski RW, Martin LB. Clarkson KA, et al. Among authors: talaat kr. Curr Top Microbiol Immunol. 2022 May 27. doi: 10.1007/82_2021_248. Online ahead of print. Curr Top Microbiol Immunol. 2022. PMID: 35616717
56 results